Brazilian Journal of Anesthesiology
https://app.periodikos.com.br/journal/rba/article/doi/10.1590/S0034-70942012000100015
Brazilian Journal of Anesthesiology
Review Article

Dexmedetomidina: papel atual em anestesia e cuidados intensivos

Dexmedetomidine: current role in anesthesia and intensive care

Joana Afonso; Flávio Reis

Downloads: 2
Views: 1042

Resumo

JUSTIFICATIVA E OBJETIVOS: Atualizar e rever a aplicação da dexmedetomidina em anestesia e cuidados intensivos. Este trabalho é uma revisão abrangente dos usos clínicos, farmacologia, farmacocinética, mecanismo de ação e efeitos adversos da dexmedetomidina. CONTEÚDO: O uso efetivo de agentes sedativo-hipnóticos e analgésicos é parte integral do conforto e segurança dos pacientes. A dexmedetomidina é um potente e altamente seletivo agonista dos adrenoceptores α-2 com propriedades simpaticolíticas, sedativas, amnésicas e analgésicas, que tem sido descrito como um adjuvante útil e seguro em várias aplicações clínicas. Proporciona uma "sedação consciente" única, analgésica, sem depressão respiratória. Os usos correntes revistos incluem sedação na unidade de tratamento intensivo - UTI (adulta e pediátrica), departamento de emergência, anestesia regional e geral, neurocirurgia, sedação para procedimentos pediátricos, intubação por fibra ótica em doentes acordados, cirurgia cardíaca e cirurgia bariátrica. CONCLUSÕES: A dexmedetomidina oferece a capacidade única de fornecer sedação e analgesia sem depressão respiratória. É um agente novo com uma grande margem de segurança, excelente capacidade sedativa e moderadas propriedades analgésicas. Embora o seu amplo uso seja, atualmente, em pacientes de unidades de cuidados intensivos cirúrgicos e não cirúrgicos, a dexmedetomidina parece ter futuras aplicações promissoras nas áreas de neuroproteção, cardioproteção e renoproteção. São necessários mais estudos detalhados para definir o seu papel como sedativo em doentes críticos, neurocirúrgicos e pediátricos, como adjuvante da anestesia e como sedativo durante procedimentos

Palavras-chave

ANALGÉSICOS, ANALGESIA, ANESTESIA, Cuidados Intensivos

Abstract

BACKGROUND AND OBJECTIVES: To update and review the application of dexmedetomidine in anesthesia and intensive care. This study is a comprehensive review of clinical uses, pharmacology, pharmacokinetics, mechanism of action and adverse effects of dexmedetomidine. CONTENT: The effective use of sedative-hypnotic agents and analgesics is an integral part of comfort and safety of patients. Dexmedetomidine is a potent and highly selective α-2 adrenoceptor agonist with sympatholytic, sedative, amnestic, and analgesic properties, which has been described as a useful and safe adjunct in many clinical applications. It provides a unique "conscious sedation", analgesia, without respiratory depression. The current reviewed uses include sedation at Intensive Care Unit - ICU (both adult and pediatric), emergency department, regional and general anesthesia, neurosurgery, sedation for pediatric procedures, awake fiber-optic intubation, cardiac surgery and bariatric surgery. CONCLUSIONS: Dexmedetomidine offers a unique ability of providing both sedation and analgesia without respiratory depression. It is a new agent with a wide safety margin, excellent sedative capacity and moderate analgesic properties. Although its wide use is currently in patients of surgical and non-surgical intensive care units, dexmedetomidine seems to have promising future applications in neuroprotection, cardioprotection and renoprotection. More detailed studies are required to define its role as sedative in critical, neurosurgical and pediatric patients, as anesthesia adjunct and sedative during procedures

Keywords

Dexmedetomidine, Anesthesia, Analgesia, Intensive Care

References

Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol. 2008;21:457-461.

Venn RM, Bradshaw CJ, Spencer R. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999;54:1136-1142.

Panzer O, Moitra V, Sladen RN. Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists. Crit Care Clin. 2009;25:451-469.

Gertler R, Brown HC, Mitchell DH. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001;14:13-21.

Clarke KW, Hall LW. "Xylazine": a new sedative for horses and cattle. Vet Rec. 1969;85:512-517.

Coursin DB, Coursin DB, Maccioli GA. Dexmedetomidine. Curr Opin Crit Care. 2001;7:221-226.

Paris A, Tonner PH. Dexmedetomidine in anaesthesia. Curr Opin Anaesthesiol. 2005;18:412-418.

Haselman MA. Dexmedetomidine: a useful adjunct to consider in some high-risk situation. AANA J. 2008;76:335-339.

Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists: their pharmacology and therapeutic role. Anaesthesia. 1999;54:146-165.

Kamibayashi T, Maze M. Clinical uses of alpha-2 adrenergic agonists. Anesthesiology. 2000;93:1345-1349.

Nelson LE, You T, Maze M. Evidence that the mechanism of hypnotic action in dexmedetomidine and muscimol-induced anesthesia converges on the endogenous sleep pathway. Anesthesiology. 2001;95.

Chrysostomou C, Schmitt CG. Dexmedetomidine: sedation, analgesia and beyond. Expert Opin Drug Metab Toxicol. 2008;4:619-627.

Dyck JB, Shafer SL. Dexmedetomidine: pharmacokinetics and pharmacodynamics. Anaesth Pharm Rev. 1993;1:238-245.

Vilo S, Rautiainen P, Kaisti K. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. Br J Anaesth. 2008;100:697-700.

De Wolf AM, Fragen RJ, Avram MJ. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg. 2001;93:1205-1209.

Penttilä J, Helminen A, Anttila M. Cardiovascular and parasympathetic effects of dexmedetomidine in healthy subjects. Can J Physiol Pharmacol. 2004;82:359-362.

Ickeringill M, Shehabi Y, Adamson H. Dexmedetomidine infusion without loading dose in surgical patients requiring mechanical ventilation: haemodynamic effects and efficacy. Anaesth Intensive Care. 2004;32:741-745.

Scholz J, Tonner PH. Alpha2: adrenoceptor agonists in anaesthesia: a new paradigm. Curr Opin Anaesthesiol. 2000;13:437-442.

Ebert TJ, Hall JE, Barney JA. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382-394.

Nelson LE, Lu J, Guo T. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003;98:428-436.

Al-Metwalli RR, Mowafi HA, Ismail SA. Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery. Br J Anaesth. 2008;101:395-399.

Yoshitomi T, Kohjitani A, Maeda S. Dexmedetomidine enhances the local anesthetic action of lidocaine via an alpha-2A adrenoceptor. Anesth Analg. 2008;107:96-101.

Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000;4:302-308.

Elvan EG, Oç B, Uzun S. Dexmedetomidine and postoperative shivering in patients undergoing elective abdominal hysterectomy. Eur J Anaesthesiol. 2008;25:357-364.

Easley RB, Brady KM, Tobias JD. Dexmedetomidine for the treatment of postanesthesia shivering in children. Paediatr Anaesth. 2007;17:341-346.

Wallace AW, Galindez D, Salahieh A. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology. 2004;101:284-293.

Jalonen J, Halkola L, Kuttila K. Effects of dexmedetomidine on coronary hemodynamics and myocardial oxygen balance. J Cardiothorac Vasc Anesth. 1995;9:519-524.

Talke P, Li J, Jain U. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery: The Study of Perioperative Ischemia Research Group. Anesthesiology. 1995;82:620-633.

Ma D, Hossain M, Rajakumaraswamy N. Dexmedetomidine produces its neuroprotective effect via the alpha2A-adrenoceptor subtype. Eur J Pharmacol. 2004;502:87-97.

Rouch AJ, Kudo LH, Hébert C. Dexmedetomidine inhibits osmotic water permeability in the rat cortical collecting duct. J Pharmacol Exp Ther. 1997;281:62-69.

Billings FT 4th, Chen SW, Kim M. Alpha 2-adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol. 2008;295:F741-748.

Ebert T, Maze M. Dexmedetomidine: another arrow for the clinician's quiver. Anesthesiology. 2004;101:568-570.

Ingersoll-Weng E, Manecke GR Jr, Thistlethwaite PA. Dexmedetomidine and cardiac arrest. Anesthesiology. 2004;100:738-739.

Videira RL, Ferreira RM. Dexmedetomidine and asystole. Anesthesiology. 2004;101.

Aho M, Erkola O, Kallio A. Comparison of dexmedetomidine and midazolam sedation and antagonism of dexmedetomidine with atipamezole. J Clin Anesth. 1993;5:194-203.

Kobayashi A, Okuda T, Kotani T. Efficacy of dexmedetomidine for controlling delirium in intensive care unit patients. Masui. 2007;56:1155-1160.

Pandharipande PP, Pun BT, Herr DL. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298:2644-2653.

Sturaitis MK, Kroin JS, Swamidoss CP. Effects of intraoperative dexmedetomidine infusion on hemodynamic stability during brain tumor resection. Anesthesiology. 2002;97.

Tanskanen PE, Kyttä JV, Randell TT. Dexmedetomidine as an anaesthetic adjuvant in patients undergoing intracranial tumour surgery: a double-blind, randomized and placebo-controlled study. Br J Anaesth. 2006;97:658-665.

Rozet I. Anesthesia for functional neurosurgery: the role of dexmedetomidine. Curr Opin Anaesthesiol. 2008;21:537-543.

Frost EA, Booij LH. Anesthesia in the patient for awake craniotomy. Curr Opin Anaesthesiol. 2007;20:331-335.

Ruesch S, Levy JH. Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery. Anesth Analg. 2002;95:316-318.

Wijeysundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med. 2003;114:742-752.

But AK, Ozgul U, Erdil F. The effects of preoperative dexmedetomidine infusion on hemodynamics in patients with pulmonary hypertension undergoing mitral valve replacement surgery. Acta Anaesthesiol Scand. 2006;50:1207-1212.

McCarty TM, Arnold DT, Lamont JP. Optimizing outcomes in bariatric surgery: outpatient laparoscopic gastric bypass. Ann Surg. 2005;242:494-498.

Ramsay MA, Saha D, Hebeler RF. Tracheal resection in the morbidly obese patient: the role of dexmedetomidine. J Clin Anesth. 2006;18:452-454.

Feld JM, Hoffman WE, Stechert MM. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth. 2006;18:24-28.

Hofer RE, Sprung J, Sarr MG. Anesthesia for a patient with morbid obesity using dexmedetomidine without narcotics. Can J Anaesth. 2005;52:176-180.

Cooper L, Samson R, Gallagher C. Dexmedetomidine provides excellent sedation for elective, awake fiberoptic intubation. Anesthesiology. 2005;103:A1449.

Jacobi J, Fraser GL, Coursin DB. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30:119-141.

Mantz J, Singer M. Importance of patient orientation and rousability as components of intensive care unit sedation. Redefining sedation. 1998:23-29.

Szumita PM, Baroletti SA, Anger KE. Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J Health Syst Pharm. 2007;64:37-44.

Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth. 2001;87:684-690.

Triltsch AE, Welte M, Homeyer P. Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Crit Care Med. 2002;30:1007-1014.

Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med. 2007;8:115-131.

Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J. 2004;97:451-455.

Chrysostomou C, Di Filippo S, Manrique AM. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med. 2006;7:126-131.

Walker J, Maccallum M, Fischer C. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res. 2006;27:206-210.

Shukry M, Kennedy K. Dexmedetomidine as a total intravenous anesthetic in infants. Paediatr Anaesth. 2007;17:581-583.

Munro HM, Tirotta CF, Felix DE. Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children. Paediatr Anaesth. 2007;17:109-112.

Ard J, Doyle W, Bekker A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesthesiol. 2003;15:263-266.

Anttila M, Penttilä J, Helminen A. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol. 2003;56:691-693.

Yuen VM, Irwin MG, Hui TW. A double-blind crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007;105:374-380.

Talon M, Woodson L, Sherwood E. Nasal dexmedetomidine is comparable to midazolam as a perioperative sedation for children. Anesthesiology. 2007;107.

Tobias JD. Dexmedetomidine to treat opioid withdrawal in infants following prolonged sedation in the pediatric ICU. J Opioid Manag. 2006;2:201-205.

Baddigam K, Russo P, Russo J. Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients. J Intensive Care Med. 2005;20:118-123.

Ramsay MA, Luterman DL. Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology. 2004;101:787-790.

Mack PF, Perrine K, Kobylarz E. Dexmedetomidine and neurocognitive testing in awake craniotomy. J Neurosurg Anesthesiol. 2004;16:20-25.

Bekker AY, Basile J, Gold M. Dexmedetomidine for awake carotid endarterectomy: efficacy, hemodynamic profile, and side effects. J Neurosurg Anesthesiol. 2004;16:126-135.

Chrysostomou C, Shiderly D, Berry D. Dexmedetomidine, a novel agent for the acute treatment of supraventricular tachyarrhythmias after pediatric cardiac surgery. Crit Care Med. 2007;8.

5dd559430e88250a1ac8fca6 rba Articles
Links & Downloads

Braz J Anesthesiol

Share this page
Page Sections